Table 1. clinicopathological parameters and VEGF-C, MMP-9 expression in BCYW and BCMEW group.
Case No. | BCYW | BCMEW | P | |
---|---|---|---|---|
Tumor size | ||||
≤2 cm | 70 | 35 | 35 | |
>2 cm | 36 | 16 | 20 | 0.588 |
Histological grade | ||||
I | 14 | 4 | 10 | |
II | 56 | 30 | 26 | |
III | 36 | 17 | 19 | 0.247 |
ER | ||||
Negative | 52 | 29 | 23 | |
Positive | 54 | 22 | 32 | 0.122 |
PR | ||||
Negative | 48 | 27 | 21 | |
Positive | 58 | 24 | 34 | 0.127 |
HER2 | ||||
Negative | 57 | 23 | 34 | |
Positive | 49 | 28 | 21 | 0.085 |
Molecular subtype | ||||
Luminal A | 44 | 18 | 26 | |
Luminal B | 19 | 9 | 10 | |
HER2 positive | 30 | 19 | 11 | |
Triple negative | 13 | 5 | 8 | 0.242 |
LNM | ||||
no | 62 | 24 | 38 | |
yes | 44 | 27 | 17 | 0.021 |
TNM staging | ||||
I | 46 | 22 | 24 | |
II | 33 | 13 | 20 | |
III | 27 | 16 | 11 | 0.312 |
VEGF-C | ||||
Negative | 42 | 22 | 20 | |
Positive | 64 | 29 | 35 | 0.476 |
MMP-9 | ||||
Negative | 61 | 24 | 37 | |
Positive | 45 | 27 | 18 | 0.035 |